According to a recent Reuters article, the FDA has asked three major drug companies to update safety restrictions for their arthritis drugs. The drugs in question belong to the class of treatments known as JAK inhibitors, which treat rheumatoid arthritis. All three drugs: Pfizer’s Xeljanz, AbbVie’s Rinvoq, and Eli Lilly’s Olumiant, currently have boxed warnings about blood clots and lymphoma. With updated warnings, the FDA is essentially pushing back the drugs’ place in the treatment sequence and limiting their use.
FDA Wants New Warnings for Arthritis Drugs
The agency is requiring Pfizer, Eli Lilly, and AbbVie to include new heart safety and cancer warnings on the drugs.
Sep 8, 2021
Sponsor Content
Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Sustainable Healthcare Packaging Solutions That Work
Industry leaders share proven strategies for reducing packaging emissions by up to 70% while meeting safety and regulatory requirements.
Read More
Downloads
